Syndax Pharmaceuticals annual free cash flow
2014
2015
2016
2017
2018
2020
2021
2022
2023
2024
2025
Syndax Pharmaceuticals Free Cash Flow (FCF) History (SNDX)
Syndax Pharmaceuticals reported −$323.2M in free cash flow for fiscal 2025, a decrease of $48.3M from the previous fiscal year, with a free cash flow margin of −187.50%.
View full Syndax Pharmaceuticals company overviewSyndax Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$323.2M | −$48.3M | — | −187.50% |
| 2024 | 2024-12-31 | −$274.9M | −$114.3M | — | −1160.91% |
| 2023 | 2023-12-31 | −$160.6M | −$26.9M | — | — |
| 2022 | 2022-12-31 | −$133.7M | −$162.7M | — | — |
| 2021 | 2021-12-31 | $29.0M | $100.3M | — | +20.76% |
| 2020 | 2020-12-31 | −$71.3M | −$2.5M | — | −4697.43% |
| 2018 | 2018-12-31 | −$68.7M | −$21.3M | — | −4529.86% |
| 2017 | 2017-12-31 | −$47.5M | −$12.0M | — | −2251.19% |
| 2016 | 2016-12-31 | −$35.4M | −$32.9M | — | −2903.11% |
| 2015 | 2015-12-31 | −$2.5M | $11.9M | — | −395.06% |
| 2014 | 2014-12-31 | −$14.4M | — | — | — |
Syndax Pharmaceuticals quarterly free cash flow
Q3.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.18
Q2.18
Q3.18
Q4.18
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2018 | 2018-12-31 | −$15.1M | −$4.6M | — | −3962.37% |
| Q3 2018 | 2018-09-30 | −$18.5M | −$7.0M | — | −4873.09% |
| Q2 2018 | 2018-06-30 | −$15.1M | −$8.2M | — | −3997.10% |
| Q1 2018 | 2018-03-31 | −$20.0M | −$13.5M | — | −5288.39% |
| Q4 2016 | 2016-12-31 | −$10.4M | −$5.2M | — | −3415.08% |
| Q3 2016 | 2016-09-30 | −$11.5M | — | — | −3771.48% |
| Q2 2016 | 2016-06-30 | −$7.0M | — | — | −2282.95% |
| Q1 2016 | 2016-03-31 | −$6.5M | — | — | −2142.95% |
| Q3 2015 | 2015-09-30 | −$5.2M | — | — | −1703.28% |
Syndax Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$71.3M to −$323.2M, a net decrease of $251.9M. Syndax Pharmaceuticals's latest reported quarter, Q4 2018, generated −$15.1M in free cash flow, a decrease of $4.6M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Syndax Pharmaceuticals filings at SEC.gov ↗